These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8946657)

  • 1. Influence of Cyp2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol.
    Linnet K; Wiborg O
    Ther Drug Monit; 1996 Dec; 18(6):629-34. PubMed ID: 8946657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol.
    Lisbeth P; Vincent H; Kristof M; Bernard S; Manuel M; Hugo N
    Eur J Clin Pharmacol; 2016 Feb; 72(2):175-84. PubMed ID: 26514968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype.
    Jaanson P; Marandi T; Kiivet RA; Vasar V; Vään S; Svensson JO; Dahl ML
    Psychopharmacology (Berl); 2002 Jun; 162(1):67-73. PubMed ID: 12107620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism.
    Linnet K; Wiborg O
    Clin Pharmacol Ther; 1996 Jul; 60(1):41-7. PubMed ID: 8689810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol.
    Jerling M; Dahl ML; Aberg-Wistedt A; Liljenberg B; Landell NE; Bertilsson L; Sjöqvist F
    Clin Pharmacol Ther; 1996 Apr; 59(4):423-8. PubMed ID: 8612387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of age and CYP2D6 genotype on exposure of zuclopenthixol in patients using long-acting injectable versus oral formulation-an observational study including 2044 patients.
    Tveito M; Smith RL; Molden E; Høiseth G
    Eur J Clin Pharmacol; 2021 Feb; 77(2):215-221. PubMed ID: 33000414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
    Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
    Psychopharmacology (Berl); 1999 Dec; 147(3):300-5. PubMed ID: 10639689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype.
    Molden E; Waade RB; Hoff M; Haslemo T
    Basic Clin Pharmacol Toxicol; 2016 Nov; 119(5):470-475. PubMed ID: 27145399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of genetic variability in CYP2D6, CYP3A5, and ABCB1 on serum concentrations of quetiapine and N-desalkylquetiapine in psychiatric patients.
    Bakken GV; Molden E; Hermann M
    Ther Drug Monit; 2015 Apr; 37(2):256-61. PubMed ID: 25254417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of CYP2D6 on serum concentrations of flupentixol, haloperidol, perphenazine and zuclopenthixol.
    Waade RB; Solhaug V; Høiseth G
    Br J Clin Pharmacol; 2021 May; 87(5):2228-2235. PubMed ID: 33118660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.
    Berecz R; de la Rubia A; Dorado P; Fernández-Salguero P; Dahl ML; LLerena A
    Eur J Clin Pharmacol; 2003 May; 59(1):45-50. PubMed ID: 12682803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
    van der Weide K; van der Weide J
    J Clin Psychopharmacol; 2015 Jun; 35(3):228-36. PubMed ID: 25868121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole.
    Hendset M; Hermann M; Lunde H; Refsum H; Molden E
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1147-51. PubMed ID: 17828532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
    Llerena A; Dorado P; Peñas-Lledó EM
    Pharmacogenomics; 2009 Jan; 10(1):17-28. PubMed ID: 19102711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
    Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
    Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of classical and new antipsychotic drugs.
    Otani K; Aoshima T
    Ther Drug Monit; 2000 Feb; 22(1):118-21. PubMed ID: 10688273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions.
    Paulzen M; Haen E; Gründer G; Lammertz SE; Stegmann B; Schruers KR; Walther S; Schoretsanitis G
    J Psychopharmacol; 2016 Aug; 30(8):803-9. PubMed ID: 27251417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of linearity of kinetics for the neuroleptics perphenazine and zuclopenthixol.
    Linnet K
    Eur J Clin Pharmacol; 1997; 52(4):317-8. PubMed ID: 9248772
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs.
    Dorado P; Berecz R; Peñas-Lledó EM; Cáceres MC; Llerena A
    Curr Drug Targets; 2006 Dec; 7(12):1671-80. PubMed ID: 17168842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relevance of CYP2D6 -1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients.
    Dorado P; Peñas-LLedó EM; de la Rubia A; LLerena A
    Pharmacogenomics; 2009 Jul; 10(7):1083-9. PubMed ID: 19604081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.